We think differently about mental health so you can too
Our vision is a world of mental wellbeing.
COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how COMP360 psilocybin therapy could help people with treatment-resistant depression.
We want to transform the patient experience in mental health care.
Our team
Everyone has a mental health story, be it their own, or that of a friend or loved one. Our people bring their stories, and a wide range of backgrounds and skills to COMPASS.
Our research
Our research is evidence-based and underpinned by a commitment to find better ways to support and empower people suffering with poor mental health.
News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology, and digital platforms.
-
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
-
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
-
COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights